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Consecutive bacillary angiomatosis and Rhodococcus equi
bacteremia during acute leukemia: zoonoses may cause
fever in neutropenic patients
Bacillary angiomatosis (BA) is a neovascular proliferative dis-
order due to Bartonella henselae or Bartonella quintana, originally
described as involving the skin and lymph nodes of human
immunode¢ciency virus (HIV)-infected patients [1,2]. BA has
rarely been reported in patients with cancer [3] or in immuno-
competent individuals [4]. Rhodococcus equi is an aerobic,
Gram-positive, facultative intracellular pathogen, mostly
responsible for necrotizing pneumonia, intestinal ulcerations
and lymphadenitis [5], in associationwithmarked impairment
of cell-mediated immunity [6].
We report the consecutive occurrence of B. henselae bacillary
angiomatosis and R. equi bacteremia in a severely neutropenic
HIV-negative adult with acute myeloblastic leukemia.
A 60-year-old HIV-negative man was admitted to our
unit in July 1994 for the treatment of chronic myeloid leuke-
mia transformed into acute myeloblastic leukemia. Initial eva-
luation did not detect any other remarkable medical
condition. The patient owned a dog but denied having any
particular contact with cats or farm animals. From July 1991 to
June 1994, he received chemotherapy consisting of hydro-
xyurea and subcutaneous injections of recombinant inter-
feron-a and cytosine-arabinoside. In July 1994, he received
one cycle of intravenous idarubicin and cytosine-arabinoside,
whichwas again started on10 August (day1), because hemato-
logic remission was not obtained. Profound neutropenia (<  
100 neutrophils/mm3) started at day 10; piperacillin and ami-
kacin had been started on day 16 because of unexplained fever.
On day 18, the patient developed multiple dome-shaped pur-
ple nodular lesions on his face, right arm and left thigh, for
which intravenous teicoplanin (500  mg/day) and fusidic acid
(500  mg three times a day) were added to the initial antibacter-
ial combination from day 18 to day 28 up to the neutrophil
recovery.
Histologic examination of two skin biopsies ¢xed in 10%
formalin and embedded in para¤n was compatible with the
diagnosis of cutaneous BA, although Grocott-Gomori and
Whartin-Starry failed to reveal anymicroorganism.
In September, the patient was readmitted for uncontrolled
leukemia necessitating treatment with intravenous che-
motherapy. At that time, skin lesions had completely disap-
peared. A non-bacteriologically documented episode of
febrile neutropenia rapidly developed which again required
intravenous piperacillin and amikacin. Fever regressed shortly
thereafter, but a new episode of sepsis occurred in October for
which the patient received intravenous imipenem^cilastatin
in combination with amikacin and teicoplanin, which transi-
ently controlled fever. At that time, three Dupont-Isolator
blood cultures were performed. The patient died shortly
thereafter of uncontrolled leukemia. No autopsy was per-
formed.
After 6  weeks of subculture on horse blood agar, one of
the last lysis^centrifugation blood cultures grew Gram-posi-
tive bacilli identi¢ed as R. equi (Api coryne¨, Biome¨rieux,
Marcy l'E¨toile, France; and Laboratoire des Identi¢cations,
Institut Pasteur, Paris, France).The strain was susceptible to all
the antibiotics usually active against corynebacteria, including
penicillin.
Molecular detection of B. henselaewas performed on serum
that had been frozen or from sections of formalin-¢xed,
para¤n-embedded skin-biopsy specimens by PCR ampli¢-
cation and sequencing of the citrate synthase gene as pre-
viously described [7]. DNA extracts suitable for use as
templates in PCRs were prepared from crushed skin-biopsy
specimens and serum using QIAmp tissue kit (Qiagen,
Hilden, Germany) according to the manufacturer's instruc-
tions. B. henselae DNAwas detected in both skin and serum
samples.The immuno£uorescence assays to detect serum anti-
bodies directed against B. henselae, B. quintana and A¢pia felis
were negative.
Our patient reported no known exposure to cats, a factor
recorded in one-third of the patients with BA [8], but he
owned a dog. Interestingly, it has been shown that Ctenocepha-
lides felis, the cat-£ea, may be culture and DNA positive for B.
henselae [9] and thatC. felis also commonly infests dogs, the lat-
ter perpetuating the £ea life cycle [10]. However, a recent
study by Koehler et al found that exposure to dog-£ea bite was
similar in patients infected with B. henselae and their matched
controls [2].
Three recent reports described cutaneous BA in patients
with chronic (n    2) or acute (n    1) leukemia [11^13] (Table  1).
Our patient was seronegative at the time of BAdiagnosis.This
lack of antibody detection may re£ect the profound immuno-
suppression observed in our patient and is in accordance with
the previous experience of the Center for Rickettsial Refer-
ence in Marseille [7, 14]. In contrast, PCR o¡ers a rapid and
speci¢c means to detect the organism [1]. B. henselaeDNAwas
detected in our patient's serum, while blood cultures analyzed
with an automated system failed to isolate the organism. Bac-
teremic episodes were reported in non-HIV-infected persons,
either immunocompromised, or immunocompetent [15].The
clinical improvement that we observed in our patient could
probably be ascribed to amikacin. Indeed, although Bartonella
spp. have been reported to be highly susceptible to antibiotics,
only the aminoglycosides were bactericidal on either axenic or
cell line-cultured organisms [16]. The lack of relapse during
the following 2  months can probably be attributed to the rein-
troduction of several antibiotics.
CORRESPONDENCE
= 2000 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 6, 334±339
R. equi infections have rarely been reported in patients
reporting contact with dogs as in our case [17]. Pertinently,
although rare, R. equi skin lesions and fecal carriage have been
reported in dogs [6], thereby raising the possibility of direct
transmission of the bacteria from this domestic animal to
immunocompromised hosts. Although blood cultures were
positive in 65% of HIV-infected patients in one report [5],
positivity was also reported in 17 non-HIV-infected patients,
including 10 with hematologic malignancies [17]. It should be
noted that the frequency of R. equi bacteremia is probably
underestimated, as blood cultures were never allowed to grow
for as long as ours (6  weeks). Among these 17 patients, 13 were
cured of their bacteremic episode [17]. R. equi is usually sensi-
tive to glycopeptides, imipenem and aminoglycosides [18],
and all of these antibiotics were empirically given in combina-
tion to our patient. Finally, it should be noted that the R. equi
strain isolated from our patient was susceptible to penicillin.
This susceptibility was found for isolates from soil and ani-
mals, but human strains were reported to be invariably resis-
tant to penicillin [19], with MICs ranging from 2 to 16  mg/L
[18].
Our case report emphasizes that zoonoses may cause fever
in HIV-negative neutropenic patients with hematologic
malignancies.
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Table  1 Description of four male HIV-negative patients with leukemia who developed bacillary angiomatosis during chemotherapy
Ref.
Age
(years)
Underlying
risk factors
Contact
with cats
Neutrophil
count
(/mm3)
Lymphocyte
count
(/mm3)
BA
diagnosis Treatment Outcome
(11) 12 ALL
steroid
chemotherapy
Unknown 820 820 Histology  EM
 PCR in skin
Erythromycin Complete resolution
(12) 78 CLL
diabetes
Yes (cat
scratch)
2430 24  300 Histology  EM Erythromycin Complete resolution
steroid,
chemotherapy
(13) 55 CLL
steroid,
chemotherapy
No 730 110 Histology  EM Clarithromycin Complete resolution
This
report
60 AML
chemotherapy
No <  100 <  100 Histologya
PCR in serum and
skin
Piperacillin 
amikacin
Complete resolution
CLL, chronic lymphocytic leukemia; AML, acute myeloblastic leukemia; ALL, acute lymphoblastic leukemia; BA, bacillary angiomatosis; PCR,
polymerase chain reaction; EM, electron microscopy.
aSilver impregnation including Warthin±Starry stain were negative.
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Combination chemotherapy for the treatment of invasive
infections by Scedosporium proli®cans
The saprophytic mold Scedosporium proli¢cans may cause inva-
sive infections in both immunocompromised and immuno-
competent hosts.The recent review byGosbell et al [1] showed
that the outcome of treatment of patients with this infection is
very disappointing, for several reasons.The fungus appears to
disseminate rapidly from the primary site of infection to dis-
tant organs, including the brain.The fungus is able to produce
spores during growth in the tissues, which facilitates dissemi-
nation and explains why this fungus is readily cultured from
the blood [1]. The poor outcome of treatment is also due to
multiresistance of this fungus to the currently available anti-
fungal agents, including amphotericin B, the azoles and £ucy-
tosine. The lack of e¡ective drugs against S. proli¢cans is in
agreement with the in vitro resistance exhibited by this patho-
gen [2], although in vitro results have not yet been correlated
directly with in vivo results. Even novel antifungal agents such
as the triazoles voriconazole, posaconazole and Syn-2869 [2,
3] and the echinocandins LY303366 and caspofungin show
limited or no invitro activity against this fungus [3, 4].
Given the lack of e¡ective antifungal agents, the possibility
of combination therapy should be considered. Although the
authors do not refer to this possibility in their review, there is
some evidence that combinations of antifungals may be e¡ec-
tive against Scedosporium species at least in vitro.The combina-
tion of amphotericin B and azoles was tested against S.
apiospermum, and was additive or synergistic for 67% of the
tested isolates [5]. Furthermore, the combination of terbina-
¢ne with azoles appears to be very active.We have recently
shown synergism between the combinations terbina¢ne^
miconazole and terbina¢ne^itraconazole against S. proli¢cans
[6]. Although terbina¢ne and itraconazole alone appeared to
be inactive against the fungus, pronounced in vitro synergism
was found for 19 of the 20 isolates (95%) after 48  h and for 17
of the 20 isolates (85%) after 72  h of incubation when these
drugs were combined [6]. For three isolates, the combination
appeared to be indi¡erent after 72  h of incubation, and antag-
onismwas not observed.The combination appeared to be also
synergistic against other fungal pathogens, including Candida
albicans [7], Candida glabrata, Cryptococcus neoformans [8], Asper-
gillus fumigatus [9] and Phytium insidiosum [10].
Terbina¢ne is an allylamine, which interacts with the path-
way of ergosterol biosynthesis by inhibiting the conversion of
squalene to 2,3-epoxidesqualene. The activity of the enzyme
squalene epoxidase is impeded by terbina¢ne, which results in
the accumulation of squalene and causes the production of
de¢cient ergosterol.The azoles inhibit a subsequent step in the
biosynthesis of fungal ergosterol by inhibiting the methyla-
tion of lanosterol by 14a-demethylase, a P-450-dependent
enzyme [11]. The interaction of terbina¢ne and azoles with
di¡erent steps of the same pathway of fungal ergosterol bio-
synthesis supports the possibility of synergism.
The in vivo extrapolation of in vitro results is always di¤-
cult, and to date there are very limited animal experimental
data that could support or contradict the observed interaction
in vitro.Terbina¢ne showed relatively little activity in combi-
nation with amphotericin B in a rabbit model of invasive
aspergillosis [12], although antagonism was not observed.
Nevertheless, there are some clinical data that suggest that the
combination terbina¢ne^itraconazole acts synergistically in
vivo. In the ¢rst case, an immunocompetent host su¡ering
from pulmonary pseudallescheriasis (S. apiospermum infection)
was cured after treatment with itraconazole followed by terbi-
na¢ne [13].The patient was treated with itraconazole at a dose
of 400  mg/day for 23  months, but after an initial response the
infection relapsed.Therapy was then changed to terbina¢ne at
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